Respiratory Research

Research

Blood neutrophil activation markers in severe asthma: lack of inhibition by prednisolone therapy

Bhupinder S Mann and Kian Fan Chung*

Address: National Heart & Lung Institute, Imperial College & Royal Brompton Hospital London, UK

Email: Bhupinder S Mann - Bobby.Mann@WMUH-TR.NTHAMES.NHS.UK; Kian Fan Chung* - f.chung@imperial.ac.uk

* Corresponding author

Abstract

Background: Neutrophils are increased in the airways and in induced sputum of severe asthma patients. We determined the expression of activation markers from circulating neutrophils in severe asthma, and their suppressibility by corticosteroids.

Methods: We compared blood neutrophils from mild, moderate-to-severe and severe steroid-dependent asthma, and non-asthmatics (n = 10 each). We examined the effect of adding or increasing oral prednisolone (30 mg/day; 1 week).

Results: Flow cytometric expression of CD35 and CD11b, but not of CD62L or CD18, was increased in severe asthma. F-met-leu-phe increased CD11b, CD35 and CD18 and decreased CD62L expression in all groups, with a greater CD35 increase in severe asthma. In severe steroid-dependent asthma, an increase in prednisolone dose had no effect on neutrophil markers particularly CD62L, but reduced CD11b and CD62L on eosinophils. Phorbol myristate acetate-stimulated oxidative burst and IL-8 release by IL-1β, lipopolysaccharide and GM-CSF in whole blood from mild but not severe asthmatics were inhibited after prednisolone. There were no differences in myeloperoxidase or neutrophil elastase release from purified neutrophils.

Conclusion: Because blood neutrophils in severe asthma are activated and are not inhibited by oral corticosteroids, they may be important in the pathogenesis of severe asthma.

Background

Asthma is characterised by reversible airways obstruction, bronchial hyperresponsiveness, and chronic inflammation of the bronchial mucosal lining. Inhaled corticosteroids, particularly in combination with long-acting β-agonists, are efficient in reducing symptoms and exacerbations. However, a proportion of patients with asthma are not controlled and have persistent symptoms, recurrent exacerbations and/or persistent airflow obstruction despite using high doses of inhaled corticosteroids, and often oral corticosteroids, and long-acting β2-agonist bronchodilators [1]. This group of patients often termed severe asthma or therapy-resistant asthma forms a distinct category of asthma [2,3]. There may be pathophysiological mechanisms that are unique for severe asthma compared to mild/moderate asthma [4]. The neutrophil may be an important inflammatory cell that contributes to the pathophysiology of severe asthma since increased neutrophilic inflammation measured in induced sputum and in the bronchial submucosa has been reported in such patients [5-7] Increased neutrophilic inflammation has also been observed under other asthmatic circumstances...
such as in patients who have died during a sudden-onset attack and in patients ventilated following an acute severe exacerbation [8,9]. In addition, increased neutrophils have been observed in airway submucosal glands in patients who have died of asthma [10].

Neutrophils may therefore be involved in the pathogenesis of asthma through their activation [11-13]. Neutrophil migration from the circulation into an area of inflammation involves regulated expression of leucocyte surface adhesion molecules. L-selectin (CD62L) is important in the initial attachment of leucocytes to endothelium, and is rapidly shed after neutrophil activation by proteolytic cleavage [14]. This is followed by tight adhesion and transendothelial migration of granulocytes mediated by β2 integrins, such as CD11b (CR3, or Mac1), one of 3 α-chain molecules, and CD18, a common β-chain. Neutrophil activation is associated with upregulation of CD11b and CD18 from intracellular storage pools, and shedding of CD62L. Neutrophils are also a potential source of inflammatory mediators such as leukotriene B4 (LTB4), and platelet-activating factor (PAF), of enzymes such as neutrophil elastase, myeloperoxidase and matrix metalloproteinases (MMP-9), of reactive oxygen species, and of cytokines such as TNFα and IL-8 [15]. Peripheral blood neutrophils and eosinophils may be activated or primed in the circulation of mild asthmatics with regards to superoxide production, chemotaxis and increased expression of surface molecules on neutrophils such as CD35, which mediates the binding and phagocytosis of C3b-coated particles and immune complexes [16]. Neutrophils have been implicated in the development of bronchial hyperresponsiveness [17]. Neutrophil elastase has the capacity to induce mucus gland hyperplasia and mucus secretion) [18] and proliferation or apoptosis of airway smooth muscle cells [19,20]. Little is known about the activation status and the role of the circulating neutrophil in severe asthma.

Glucocorticoids, an important treatment for asthma, exert inhibitory effects on neutrophil activation and functions such as chemotaxis, free radical generation, and adhesion [21-24]. They also inhibit neutrophil apoptosis, while decreasing eosinophil survival by increasing eosinophil apoptosis [25]. Treatment of mild asthmatics with prednisolone induces an increase in neutrophils in the airways mucosa [26], but in patients with chronic obstructive airways disease, corticosteroids have very little effect on airway inflammation [27,28]. In the present study, we have investigated the expression of the cell-surface molecules CD11b, CD62L, CD18 and CD35 on resting and stimulated neutrophils, together with respiratory burst activity, myeloperoxidase and neutrophil elastase release, and IL-8 cytokine levels from blood cells in different categories of patients with asthma. We have categorised our asthmatics into a group of severe corticosteroid-dependent asthmatics on both inhaled and oral corticosteroid therapies, compared to a group of moderate-to-severe asthmatics only on inhaled corticosteroid therapy and a group of mild asthmatics. We also studied the effect of oral pred-

| Table 1: Clinical characteristics of controls and asthmatic patients |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|
|                                 | Mild asthma     | Moderate-to-severe asthma | Severe steroid-dependent asthma | Non-asthma controls |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|
| n                               | 10              | 10              | 10              | 10              |
| Gender M:F                      | 2:8             | 4:6             | 4:6             | 7:3             |
| Mean age (years) [range]        | 35.8 [22–49]    | 47.7 [31–73]    | 50.9 [45–66]    | 36 [32–45]      |
| FEV1 (% predicted) [range]      | 95.8 ± 3.3 [75–112] | 66.7 ± 5.0 [38.5–85] | 51.4 ± 3.7 [30–70.7] | 95 [92–98]     |
| Inhaled corticosteroid dose (BDP equivalent µg/day) | 0 | 1,900 ± 100 | 2,000 ± 0 | 0 |
| Atopy                           | 7               | 10              | 5               | 0               |
| Exhaled NO (ppb) [range]        | 27.1 [6.2–94]   | 46.9 [9.2–102]  | 30.8 [10.4–65.2] | ND              |

M: male; F: female; NO: nitric oxide; ND: not determined.
*: Atopy defined as positive skin prick test to 2 common aeroallergens
1: Data shown as mean ± SEM
nistrans and inhaled corticosteroids (beclomethasone dipropionate, 2000 µg/day or equivalent), and with maintenance oral prednisolone (> 5 mg per day for at least one year). The mean maintenance dose of oral prednisolone was 14 mg/day (range 10–20 mg/day).

Atopic status was evaluated by skin prick tests to Dermatophagoides pteronyssinus, mixed grass pollen, and cat hair. FEV1 was measured with a calibrated, dry-wedge spirometer (Vitalograph, Buckingham, UK). All patients gave informed consent, and the study was approved by the Royal Brompton Hospital Ethics Committee.

**Effect of prednisolone**

The effect of prednisolone on neutrophil function in peripheral blood was determined by treating mild asthma patients with prednisolone 30 mg/day for 1 week, and steroid-dependent patients with a dose of 30 mg/day added to their usual maintenance dose for one week. Blood samples were obtained before and on the day after the seventh dose of prednisolone had been taken. The study was not blinded or placebo-controlled, but the person analysing the cells ex-vivo was blinded to the treatment received by the asthmatics.

**Surface molecule expression**

Fluorescein isothiocyanate (FITC)-conjugated monoclonal antibodies directed against CD11b, CD62L (L-selectin), CD35 and CD18, along with the appropriate isotype controls (Serotec Ltd, Oxford, UK) and phycoerythrin (PE)-conjugated CD16 monoclonal antibody (Becton Dickinson, Oxford, UK) were added to heparinised whole blood (100 µl) at 4°C for 30 min in the dark. Cells were washed with phosphate-buffered saline (PBS, Gibco, Invitrogen, UK) containing 0.5% bovine serum albumin (BA, Sigma Aldridge, Poole, UK) and 0.5% sodium azide (Sigma Aldridge, Poole, UK). After centrifugation (5 minutes; 1800 rpm) the supernatant was discarded and 2 ml of freshly-prepared Erythrolyse (Serotec Ltd, Oxford, UK) were added (10 min; room temperature). Cells were then washed with 2 ml PBS-BA and centrifuged as above and resuspended in 0.5 ml of 0.5% paraformaldehyde (Sigma Chemical Co, Poole, UK).

**Stimulation of whole blood**

Blood was incubated with N-formyl-methionyl-leucine-phenylalanine (FMLP 10-7M, Sigma Aldridge, Poole, UK) for 10 min at 37°C. The reaction was stopped by adding cold PBS solution. The tubes were then centrifuged for 5 min at 1800 rpm and the supernatant discarded. Blood was then incubated with conjugated monoclonal antibodies.
**Flow cytometry**

Flow cytometry was performed using a FACScan analyser (Becton Dickinson, Oxford, UK) with Argon-ion laser. Fluorescence gain was adjusted using a gate drawn around the granulocyte population on an unstained lysed whole blood sample, and then placing this population in the first log decade. Compensation was set by using blood incubated with either FITC- or PE-labelled monoclonal antibodies in order to correct for spectral overlap. As an instrumental control measure, CaliBRITE beads (Becton Dickinson) were used to ensure the correct alignment and calibration of the flow cytometer. Ten thousand events were collected from each sample. We used the method described by Gopinath et al for identification of neutrophils and eosinophils in lysed whole blood using side scatter and CD16 negativity [29]. Granulocytes were discriminated from other cell populations by their characteristic high side and forward light scatter. A gate was drawn around the granulocytes which was reflected into a dot-plot of side-scatter and CD16, showing neutrophils as CD16-positive cells with eosinophils as CD16-negative cells with high side scatter. Purity of the neutrophil and eosinophil populations determined was close to 99% on cells with high side scatter. Purity of the neutrophil and CD16-positive cells with eosinophils as CD16-negative was then drawn around the neutrophil (CD16+) or eosinophil (CD16-) populations and reflected into a histogram so that cells can be labelled with a further fluorochrome (eg. CD11b or CD18). Results were recorded as mean fluorescence intensity (MFI) which represents the cell surface receptor density.

**Oxidative burst and elastase measurements**

Respiratory burst was measured according to the method of Rothe and Valet [30]. Briefly, 3 ml of heparinised blood was layered onto 3 ml of Ficoll Hypaque medium (Amer- sham Biosciences, UK) and left at room temperature for 45 min. The supernatant (800 µl) was then removed and transferred to an Eppendorf tube and stored on ice. Hank’s balanced salt solution (HBSS, 1 ml; Sigma Aldridge, Irvine, UK) was added to 20 µl of cell suspension and 10 µl of dihydroxymadine 123 (DHR123, 1 x 10⁻³M, Molecular Probes, Upssala, Sweden), and the cells were incubated for 5 min at 37°C. Phorbol myristate acetate (PMA, Sigma Aldridge, Poole, UK; final concentration 1 µM) was added for 20 min at 37°C. Reagent blank tubes were prepared by adding only PBS to the cell suspension, while resting cells were initially incubated with PBS, followed by the addition of dihydroxymadine.

Elastase was also measured according to the method described by Rothe and Valet [31]. HBSS supplemented with 10 mM HEPES (Sigma Aldridge, Poole, UK; 1 ml) was added to 20 µl cell suspension, and 1 µl (N-benzyloxy carbonyl-Ala-Ala)-rhodamine 110 (Molecular probes, Upssala, Sweden; final concentration 4 µM). The samples were analysed on the flow cytometer after 20 min.

**Whole blood culture**

Venous blood was collected in heparinized tubes and diluted 1:10 with RPMI 1640 (Gibco, Invitrogen, UK) containing 10% fetal calf serum (FCS), 100 U/ml penicillin, 100 µg/ml streptomycin and 2 mM L-glutamine. The whole blood culture was set up so that unstimulated cells were placed in the first log decade. DHR 123 reacts with hydrogen peroxide as a result of the respiratory burst to give rhodamine which emits a green fluorescence which was measured on the FL1 channel at a wavelength of 530 nm.

**Myeloperoxidase release from purified neutrophils**

Granulocytes were isolated by Ficoll-Hypaque gradient centrifugation of heparinised whole blood (20 ml). After centrifugation (2000 rpm; 20°C; 20 min), all the layers above the red cells were removed and 10 ml PBS and 3 ml 3% Dextran T-500 (Pharmacia Biotech, Uppsala, Sweden) were added. The supernatant was centrifuged and red cells were lysed by adding 2 ml 10% HBSS in distilled water for 20 seconds, following which excess HBSS (minimum 12

---

Figure 2

Mean fluorescence intensity of CD35 expression on neutrophils from 10 normal, 10 mild, 10 moderate-to-severe and 10 severe steroid-dependent asthma patients before (open bars) and after (striped bars) stimulation with f-met-leu-phe (FMLP). **p < 0.01, *** p < 0.0001, compared to resting levels; +p = 0.02 compared to level from FMLP-stimulated blood from normal volunteers.
well plate and incubated with IL-β cyttes (1 × 10⁶/ml) were then added to 1 ml wells of a 48- various stimulants effects of prednisolone therapy or of the stimulation with ney U-test, with application of Bonferroni correction. The groups and controls were evaluated using the Mann-Whit- standard error of the mean (SEM). Differences between each of the marker expression between groups were evaluated using 48-minute, and incubated at 37°C under 5% CO₂. After each time-point, the plates were centrifuged (1800 rpm; 5 min) following which the supernatant was withdrawn and stored at -70°C until analysed for MPO levels.

Enzyme-linked immunosorbent assay (ELISA)
IL-8 (duoset, R&D systems, Oxon, UK) and neutrophil myeloperoxidase (MPO; Calbiochem, San Diego, USA) concentrations were measured in the culture supernatants with specific immunoassay kits according to the manufacturer's instructions. The detection limit was 31.2 pg/ml for IL-8 and 1.6 ng/ml for MPO.

Statistical analysis
Unless otherwise stated, data are expressed as mean ± standard error of the mean (SEM). Differences in surface marker expression between groups were evaluated using Kruskall Wallis test. Differences between each of the groups and controls were evaluated using the Mann-Whitney U-test, with application of Bonferroni correction. The effects of prednisolone therapy or of the stimulation with various stimulants in vitro were analysed by the Wilcoxon signed-rank test. A p value of 0.05 or less was considered to be statistically significant.

Results
Surface molecule expression on lysed whole blood
In unstimulated blood, there was an increased expression of CD35 and CD11b on neutrophils in patients with severe steroid-dependent asthma compared to mild and moderate-to-severe asthmatics, and non-asthmatic volun- neurs (p < 0.05). There were no significant differences in the expression of CD62L or CD18 between the groups (Fig 1).

Stimulation of blood with FMLP increased the expression of CD11b, CD35, and CD18 surface molecules on gated neutrophils in all groups of patients; there was concomi- tantly a significant decrease in CD62L in all groups. The increase in CD35 expression after stimulation with both FMLP was greater in severe asthmatics compared to that seen in non-asthmatic volunteers (p = 0.02; Fig 2), but was not significantly different compared to the other asth- matic groups.

Prednisolone had no effect on the expression of CD11b, CD62L, CD35 or CD18 on neutrophils from the 10 severe corticosteroid-dependent (Fig 3). In the 10 mild asthmatics, there was a significant decrease in the level of CD62L after prednisolone (Fig 3); this decrease was from a higher baseline expression of CD62L, though not statistically dif- ferent from neutrophils from severe asthma patients. In contrast, no difference was seen in the baseline expression of the above surface molecules on peripheral blood eosi- nophils between the patient groups (data not shown). Following prednisolone, however, there was a significant reduction in the expression of CD11b and CD62L on eos- nophils in both mild and severe patients, and a reduction in CD18 in mild asthmatics (Fig 4).

Oxidative burst in peripheral blood neutrophils
PMA stimulated the oxidative burst in granulocytes in a dose-dependent manner, with maximal stimulation achieved after 20 min (data not shown). The oxidative burst in mild asthmatics was greater than that in normal subjects (p = 0.02), while similar levels of oxidative burst were seen between normal subjects and severe asthma patients (Fig 5). After prednisolone, the oxidative burst was reduced in mild asthma patients but not in severe patients.

Release of IL-8 from whole blood culture
In unstimulated blood, IL-8 was not detectable in serum in patients with mild or severe asthma but after 24 hours, IL-8 was detectable. IL-8 levels from mild asthmatics were not significantly elevated after stimulation with IL-1β, LPS, and GM-CSF compared to severe asthmatics. In the
mild group, however, there was a significant decrease in IL-8 production induced by IL-1β, LPS and GM-CSF following prednisolone therapy; this effect of prednisolone was not seen in the severe group (Fig 6). There were no significant differences in the release of IL-8 in the pre-prednisolone blood between the patients mild and severe asthma.

**Neutrophil elastase and myeloperoxidase release from neutrophils**

Flow cytometric analysis of whole blood showed no difference in the baseline level of neutrophil elastase between mild or severe asthmatics, and there was no significant effect of prednisolone on these levels. No significant difference was seen in the baseline or IL-β-stimulated MPO levels in purified blood neutrophils between the mild and severe asthmatics. There was no significant effect of prednisolone on the MPO levels in either group.

**Discussion**

We determined whether circulating neutrophils in patients with severe asthma exhibited evidence of activation in terms of expression of surface markers or mediator release. CD35 and CD11b expression was higher on resting peripheral blood neutrophils in severe steroid-dependent asthmatics compared to normal and mild asthmatics, suggesting that neutrophils are in a more activated state in the circulation of severe asthmatics. In addition, CD35 expression on neutrophils from severe asthmatics was increased further above that seen in normal patients following stimulation of whole blood with fMLP. No difference in the expression of these surface molecules was seen on eosinophils in any of the groups.

In previous studies of neutrophil surface marker expression in asthma, no differences in expression of CD11b and CD62L had been observed compared to non-asthmatic controls [32], although an elevation in CD35 had been reported [16]. These are in contrast to the current results showing no significant differences in expression of CD35, CD11b and CD62L in mild and moderate asthmatics compared to normal volunteers. However, in this first study of blood neutrophils in severe asthma, we found an increase in CD35 and CD11b expression in patients with severe steroid-dependent asthma. Stimulation of neutrophils with fMLP increased expression of CD11b on neutrophils and eosinophils to a larger extent in children with mild asthma than in controls [16]. We found no such differences in our adults with mild asthma, but CD35 was slightly more inducible on neutrophils from severe steroid-dependent asthmatics. The discrepancies between these studies are not clear, but may relate to the age of the patients, to methodological differences in assaying these markers and to the grading of severity of the patients.

The cause of the increase in CD35 and CD11b expression on neutrophils from patients with severe asthma is unclear. One confounding factor is that the patients with severe asthma were on chronic oral prednisolone therapy which can induce blood neutrophilia attributable to bone marrow release of neutrophils, and also to mobilisation of a maturing blood pool [33,34]. Prednisolone treatment of mild asthmatics did not result in an increase in CD35 or CD11b expression, suggesting that the recruitment of new neutrophil pools may not be the cause of the increase seen in severe asthma. However, an inhibition in neutrophil CD62L expression by corticosteroids as observed in mild asthmatics has been attributed to a direct inhibition of CD62L expression in the maturation pool of bone marrow neutrophils [35]. It is likely that the increase in CD35 and CD11b may be a specific abnormality of circulating neutrophils in severe asthma. An intriguing feature is that the enhanced expression of CD11b was not accompanied by a reciprocal increase in the CD18 expression, since CD11b and CD18 constitute the Mac-1 integrin. On the other hand, it is also possible that there is enhanced shedding of CD18 or a redistribution of CD18 complexes with the CD11 family.

One of the problems of doing comparative studies of these groups of asthmatic patients separated according to disease severity is that the severe group is usually on chronic prednisolone therapy and it is difficult to exclude the effects of such therapy on neutrophil function in the severe asthma group as accounting for any observed dif-

---

**Figure 4**

Mean fluorescence intensity (MFI) of CD11b, CD62L, CD35 and CD18 expression on blood eosinophils in 10 mild and 9 severe steroid-dependent asthmatics before (pre) and after (post) a course of prednisolone therapy; this effect of prednisolone was not seen in the severe group (Fig 6). There were no significant differences in the release of IL-8 in the pre-prednisolone blood between the patients mild and severe asthma.
We found no effect of prednisolone on the expression of CD11b, CD62L, CD35 or CD18 in severe asthma, while, in mild asthma, prednisolone caused a significant decrease in CD62L expression without affecting the expression of CD35, CD11b and CD18. Thus, while the expression of CD62L by prednisolone was suppressed in mild asthma, this was not the case in severe asthma. Our observation in mild asthma patients is consistent with two reports of reduction in CD62L expression following intravenous dexamethasone in normal individuals [36,37]; similarly, high doses of corticosteroids decreased CD62L and CD11b in patients with multiple sclerosis and in patients undergoing cardio-pulmonary bypass [38,39]. The reduction of surface molecule CD62L expression by glucocorticoids may occur on segmented neutrophils within the maturation pool of the bone marrow but not on neutrophils already in the circulation [35]. This may be one mechanism of the anti-inflammatory action of glucocorticoids in mild asthma, whereby the initial weak binding of leucocytes to the endothelium mediated by L-selectin molecules such as CD62L is reduced. By contrast, the lack of inhibitory effect of corticosteroids on CD62L in severe asthmatics may allow granulocyte recruitment into inflammatory sites to continue. This lack of inhibitory effect appears to be selective for neutrophils since surface molecule expression of CD62L on eosinophils from both mild and severe patients were reduced by prednisolone to a similar extent. Thus, in severe asthma, blood eosinophils were sensitive while neutrophils appear to have lost their sensitivity to the effects of increased oral dose of prednisolone.

In addition to the loss of the effect of prednisolone on neutrophil surface markers in severe asthma, there was also lack of inhibition on the stimulated release of IL-8, and oxidative burst. Levels of IL-8 after whole blood culture were not significantly different between mild and severe steroid-dependent asthmatics, but IL-8 levels from severe patients were less readily suppressed after a course of prednisolone compared to mild asthmatics. It must be noted that although neutrophils stimulated with IL-1β, LPS and GM-CSF may be an important source of IL-8, other cells such as monocytes may also be contributory. We conclude that either of these cells were likely to represent the site of reduced corticosteroid responsiveness seen in the blood samples of patients with severe asthma.

The oxidative burst activity of neutrophils was greater in mild asthmatics compared to normal patients and severe asthma patients. Furthermore, prednisolone decreased oxidative burst activity in neutrophils from mild asthmatics, as reported previously in isolated bovine neutrophils [40], but there was no significant effect in the severe patients. Prolonged corticosteroid therapy may lead to inhibition of neutrophil superoxide production, possibly through inhibition of NADPH oxidation or impairment of other transduction mechanisms in the respiratory burst [23]. It is possible that the loss of suppressibility of the oxidative burst to prednisolone in severe asthma could be due to the reduced basal release possibly induced by chronic prednisolone therapy. Examination of the effect of prednisolone in normal volunteers in whom the baseline respiratory burst is similar to that of severe asthma patients would resolve the issue as to whether suppression is possible.

In comparison to whole blood release, when neutrophils were purified and studied in vitro, no difference was seen in the basal or IL-1β stimulated myeloperoxidase release from purified granulocytes between normal, mild, or severe asthmatics. The isolation procedure itself may alter the neutrophil to such an extent as to abolish any differences in activation. Monocytes are a source of myeloperoxidase but we have not studied monocytes in this study. No difference was seen in peripheral blood neutrophil elastase levels between mild and severe asthmatics using a flow cytometric method of analysis. Increased levels of neutrophil elastase have been reported in sputum from asthmatics with an exacerbation due to a respiratory tract infection [41], and in patients in status asthmaticus.
undergoing mechanical ventilation in the absence of infection [8,9].

What is the relevance of our findings on circulating blood neutrophils and on the pathophysiology of the airways of severe asthma? The lack of inhibition of CD62L expression and of the release of reactive oxygen species and IL-8 by prednisolone may explain why there may be ongoing inflammation and asthma in patients with severe asthma. Heightened expression of CD62L may increase the ability of the neutrophil to transmigrate from the circulation into the airway submucosa. Interestingly, the ability of prednisolone to suppress the eosinophil expression of CD11b and CD62L in severe asthma would indicate that eosinophils may be less likely to contribute to the pathophysiological changes in the airways. The lack of inhibition of IL-8 release would also lead to increased neutrophilic inflammation since IL-8 is considered to be an important molecule for the development of neutrophilic inflammation in asthma. Concentrations of IL-8 are correlated with neutrophil accumulation in asthmatic airways [7], and IL-8 is increased in bronchoalveolar lavage fluid and serum of asthma patients [42,43]. A recent study suggested that neutrophils that have migrated to IL-8 may subsequently cause eosinophils to accumulate to the asthmatic airways [44].

Why is the blood neutrophil less responsive to corticosteroids? Previous studies on circulating blood cells have focused on the peripheral blood mononuclear cell as being the site of corticosteroid resistance [45,46]. Decreased binding affinity of the glucocorticoid receptor (GR), increased expression of the alternatively-spliced variant GR-β, increased binding of the activated GR receptor to pro-inflammatory transcription factors such as AP-1 and reduced recruitment of histone deacetylase have all been implicated as the cellular basis for this resistance to corticosteroids [45,47-49]. High levels of GR-β have been reported in neutrophils, and these may be upregulated by IL-8 [50].

**Conclusion**

The circulating neutrophil in severe asthma shows evidence of activation, as measured by the increased expression of the adhesion molecules, CD11b and CD35, and of resistance to the effects of prednisolone. The neutrophil may be an important contributor to the inflammatory process in severe asthma, and further studies are needed on lung neutrophils to support this notion. The mechanism of loss of corticosteroid inhibition of neutrophils in severe asthma is not known and deserves further study.

**Competing interests**

The author(s) declare that they have no competing interests.

**Authors’ contributions**

KFC designed the project, BSM carried out all the studies and both wrote up the manuscript.

**Acknowledgements**

This work was supported by an Imperial College Trust fund.

**References**

1. Chung KF, Godard P, Adelroth E, Ayres J, Barnes N, Barnes P, Bel E, Burney P, Chanez P, Connett G, Corrigan C, de Bj, Fabbri L, Holgate ST, Ind P, Joos G, Kerstjens H, Leuenberger P, Lofdal CG, McKenzie S, Magnusson H, Postma D, Saetta M, Salmeron S, Sterk P. Difficult/therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficult/Therapy-Resistant Asthma. European Respiratory Society [In Process Citation]. Eur Respir J 1999, 13:1198-1208.

2. Robinson DS, Campbell DA, Durham SR, Pfeffer J, Barnes PJ, Chung KF. Systematic assessment of difficult-to-treat asthma. Eur Respir J 2003, 22:470-477.

3. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Respir J 2003, 22:478-483.

4. Stirling RG, Chung KF. Severe asthma: definition and mechanisms. Allergy 2001, 56:825-840.

5. Jatakanon A, Uasuf C, Maziak W, Lim S, Chung KF, Barnes PJ. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 1999, 160:1532-1539.
6. Wenzel SE, Schwartz LB, Langmack EL, Halliday JL, Trudeau JB, Gibbs RL, Chu HW: Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999, 160:1001-1008.

7. Gibson PG, Simpson JL, Salton N: Heterogeneity of airway inflammation in persistent asthma: evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest 2001, 119:1329-1336.

8. Sur S, Crotty TB, Kephart GM, Hyma BA, Colby TV, Reed CE, Hunt LW, Gleich GJ: Sudden-onset fatal asthma: A distinct entity with few eosinophils and relatively more neutrophils in the airway submucosa. Am Rev Respir Dis 1993, 148:713-719.

9. Tonnel AB, Gosset P, Tillie-Leblond I: Characteristics of the Inflammatory response in bronchial lavage fluids from patients with status asthmaticus. Int Arch Allergy Immunol 2001, 124:267-271.

10. Marigoglou NG, Mutludzic S, James AL: Increased mast cells and neutrophils in submucosal mucous glands and mucus plugging in patients with asthma. Thorax 2002, 57:677-682.

11. Ennis M: Neutrophils in asthma pathophysiology. Curr Allergy Asthma Rep 2003, 3:119-165.

12. Tillie-Leblond I, Gosset P, Tonnel AB: Inflammatory events in severe acute asthma. Allergy 2005, 60:23-29.

13. Linden A: Role of interleukin-17 and the neutrophil in asthma. Int Arch Allergy Immunol 2001, 126:179-184.

14. Ley K, Gaethgens P, Fennie C, Singer MS, Lasky LA, Rosen SD: Lectin-like cell recognition molecule 1: induction of mucociliary clearing in mesenteric venules in vivo. Blood 1991, 77:2553-2557.

15. Hampton MB, Kettle AJ, Winterbourn CC: Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. Blood 1998, 92:3007-3017.

16. Berends C, Hoepner MG, Dijkhuizen L, De Monchy JG, Gerritsen J, Aebi H, Nakagawa S, Kondo M: Methylprednisolone-induced neutrophil leukocytosis--down-regulation of marrow release and demargination of intravascular granulocytes. Circulation 1998, 98:2307-2313.

17. Chung KF: Role played by inflammation in the hyperreactivity of the airways in asthma. Thorax 1988, 43:657-662.

18. Voynow JA, Fischer BM, Malarkey DE, Burch LH, Wong T, Longhre M, Ho SB, Foster WM: Neutrophil elastase induces mucus cell metaplasia in mouse lung. Am J Physiol Lung Cell Mol Physiol 2004, 287:L1293-L1302.

19. Oltmanns U, Sukkar MB, Xie S, John M, Chung KF: Induction of human airway smooth muscle apoptosis by neutrophils and neutrophil elastase. Am J Respir Cell Mol Biol 2005, 32:334-341.

20. Huang CD, Chen HH, Wang CH, Chou CL, Lin SM, Lin HC, Kuo HP, Human neutrophil-derived elastase induces airway smooth muscle cell proliferation. Life Sci 2004, 74:2479-2492.

21. Yoshida N, Yoshihawa T, Nakamura Y, Takenaka S, Sakamoto K, Manabe H, Nakagawa S, Kondo M: Methylprednisolone inhibits neutrophil-endothelial cell interactions induced by interleukin-8 under flow conditions. J Leukoc Biol 1997, 60:2341-2347.

22. Filep JG, Delandre A, Payette Y, Folds-Filep E: Glucocorticoid receptor regulates expression of L-selectin and CD11b/CD18 on human neutrophils. Circulation 1997, 96:295-301.

23. Fukushima K, Ando M, Ito K, Suga M, Araki S: Stimulation and dose-dependent inhibition of O2- production by polymorphonuclear leukocytes of patients receiving corticosteroids. J Clin Lab Immunol 1990, 33:117-123.

24. Hirasaawa N, Watanabe M, Sue S, Watanabe K, Tsurufuli S, Ohuchi K: Induction of neutrophil infiltration by rat chemoattractant (CINC) and its inhibition by dexamethasone in rats. Inflammation 1992, 16:187-196.

25. Liles WC, Dale DC, Klebanoff SJ: Glucocorticoids inhibit apoptosis of human neutrophils. Blood 1995, 86:3181-3188.

26. Nguyen LT, Lim S, Oates T, Chung KF: Increase in airway neutrophils after oral but not inhaled corticosteroid therapy in mild asthma. Respir Med 2005, 99:200-207.

27. Chanez P, Bourdin A, Vacher I, Godard P, Bousquet J, Vignola AM: Effects of inhaled corticosteroids on pathology in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2004, 1:184-190.

28. Czuel M, Damon M, Chanez P, Bousquet J, Crastes de Paulet A, Michel FB, Godard P: Enhanced alveolar cell lumino-dependent chemiluminescence in asthma. J Allergy Clin Immunol 1987, 80:195-201.

29. Gopinath R, Nutman TB: Identification of eosinophils in lysed whole blood using side scatter and CD16 negativity. Cytometry 1997, 29:313-316.

30. Rothe G, Valet G: Measurement of phagosomal hydrogen peroxide production with dihydrorhodamine 123. In Handbook of Flow Cytometry Methods Edited by: Robinson JP. New-York, Wiley-Liss; 1994.

31. Rothe G, Valet G: Measurement of neutrophil elastase activity with (N-Benzoyloxycarbonyl-Ala-Ala)2-Rhodamine 110. In Handbook of Flow Cytometry Methods Edited by: Robinson JP. New-York, Wiley-Liss; 1994.

32. In Y, Grootendorst DC, Bel EH, Smits HH, Van Der KM, Sterk PJ, Hiemstra PS: CD11b and L-selectin expression on eosinophils and neutrophils in blood and induced sputum of patients with asthma compared with normal subjects. Clin Exp Allergy 1998, 28:606-615.

33. Nakagawa M, Terasa Kiy T, D’Achekova Y, Bondy GP, Hogg JC, van der Heide SF: The effect of glucocorticoids on the expression of L-selectin on polymorphonuclear leukocyte. Blood 1999, 93:799-805.

34. Burton JL, Kehrli MEJ, Kapil S, Horst RL: Regulation of L-selectin and CD18 on bovine neutrophils by glucocorticoids: effects of cortisol and dexamethasone. J Leukoc Biol 1995, 57:317-325.

35. Jilma B, Voitmann J, Albinini S, Stohlawaetz P, Schwarzinger I, Greilich CH, Rauch A, Eichler HG, Wagner OF: Dexamethasone down-regulates the expression of L-selectin on the surface of neutrophils and lymphocytes in humans. Clin Pharmacol Ther 1997, 62:562-568.

36. Croacker AO, Boylan MT, Droogan AG, McMillan SA, Hawkins SA: Methylprednisolone-induced neutrophil leucokytocosis--down-modulation of neutrophil L-selectin and Mac-1 expression and induction of granulocyte-colony stimulating factor. Int J Clin Lab Res 1998, 28:110-115.

37. Hill GE, Alonso A, Thiele GM, Robbins RA: Glucocorticoids blunt neutrophil CD11b surface glycoprotein upregulation during cardiopulmonary bypass in humans. Anesth Analg 1994, 79:23-27.

38. Hoenen D, Burvenich C, Massart-Leen AM: Glucocorticosteroids and in vitro effects on chemiluminescence of isolated bovine blood granulocytes. Eur J Pharmacol 1998, 354:197-203.

39. Fahy JV, Kim KW, Liu J, Boushey HA: Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. J Allergy Clin Immunol 1995, 95:843-852.

40. Terran LM, Campos L, Beghelli BL, Schroeder JM, Djukanovic R, Shute JK, Church MK, Holgate ST, Davies DE: Identification of neutrophil chemotactic factors in bronchoalveolar lavage fluid of asthmatic patients. Clin Exp Allergy 1997, 27:396-405.

41. Folkard SG, Westwick J, Millar AB: Production of interleukin-8, RANTES and MCP-1 in intrinsic and extrinsic asthmatics. Respir J 2007, 10:2097-2104.

42. Kikuchi I, Kikuchi S, Kobayashi T, Hagiwara K, Sakamoto Y, Kanazawa M, Nagata M: Eosinophil Trans-baseMembrane Migration Induced by Interleukin-8 and Neutrophils. Am J Respir Cell Mol Biol 2006.

43. Iruse E, Matthews JG, Takahashi A, Barnes PJ, Chung KF, Adcock IM: p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. J Allergy Clin Immunol 2002, 109:649-657.

44. Leung DYM, Hamid Q, Vottero A, Szefler SJ, Surs W, Minshall E, Chrousos GP, Klemm DJ: Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor beta. J Exp Med 1997, 186:1541-1547.

45. Hamid QA, Wenzel SE, Hauk PJ, Tsiopoulos A, Wallaert B, Lafitte JJ, Chrousos GP, Szefler SJ, Leung DY: Increased glucocorticoid receptor beta in airway cells of glucocorticoid-insensitive asthma. Am J Respir Crit Care Med 1999, 159:1600-1604.
48. Cosio BG, Mann B, Ito K, Jazrawi E, Barnes PJ, Chung KF, Adcock IM: Histone Acetylase and Deacetylase Activity in Alveolar Macrophages and Blood Mononocytes in Asthma. Am J Respir Crit Care Med 2004.

49. Adcock IM, Lane SJ, Brown CR, Lee TH, Barnes PJ: Abnormal glucocorticoid receptor-activator protein 1 interaction in steroid-resistant asthma. J Exp Med 1995, 182:1951-1958.

50. Strickland I, Kisich K, Hauk PJ, Vottero A, Chrousos GP, Klemm DJ, Leung DY: High constitutive glucocorticoid receptor beta in human neutrophils enables them to reduce their spontaneous rate of cell death in response to corticosteroids. J Exp Med 2001, 193:585-593.